[HTML][HTML] Measurable residual disease in chronic myeloid leukemia

S Branford, JF Apperley - Haematologica, 2022 - ncbi.nlm.nih.gov
Chronic myeloid leukemia is characterized by a single genetic abnormality resulting in a
fusion gene whose mRNA product is easily detected and quantified by reverse-transcriptase …

Measurable residual disease in chronic myeloid leukemia.

S Branford, JF Apperley - Haematologica, 2022 - europepmc.org
Chronic myeloid leukemia is characterized by a single genetic abnormality resulting in a
fusion gene whose mRNA product is easily detected and quantified by reverse-transcriptase …

Measurable residual disease in chronic myeloid leukemia.

S Branford, JF Apperley - 2022 - digital.library.adelaide.edu.au
Chronic myeloid leukemia is characterized by a single genetic abnormality resulting in a
fusion gene whose mRNA product is easily detected and quantified by reverse-transcriptase …

[HTML][HTML] Measurable residual disease in chronic myeloid leukemia

S Branford, JF Apperley - Haematologica, 2022 - haematologica.org
Chronic myeloid leukemia is characterized by a single genetic abnormality resulting in a
fusion gene whose mRNA product is easily detected and quantified by reverse-transcriptase …

Measurable residual disease in chronic myeloid leukemia

S Branford, JF Apperley - Haematologica, 2022 - pubmed.ncbi.nlm.nih.gov
Chronic myeloid leukemia is characterized by a single genetic abnormality resulting in a
fusion gene whose mRNA product is easily detected and quantified by reverse-transcriptase …

[HTML][HTML] Measurable residual disease in chronic myeloid leukemia

S Branford, JF Apperley - Haematologica, 2022 - haematologica.org
Chronic myeloid leukemia is characterized by a single genetic abnormality resulting in a
fusion gene whose mRNA product is easily detected and quantified by reverse-transcriptase …

[引用][C] Measurable residual disease in chronic myeloid leukemia

S Branford, JF Apperley - Haematologica, 2022 - europepmc.org
Monitoring residual disease has been integral to the management of chronic myeloid
leukemia (CML) for more than 30 years, and has paved the way for the introduction of similar …